CD8 T cells in the tumor are believed to be specific for tumor associated antigens and a recent analysis of the TCRβ repertoire (both CD4 and CD8 T cells) in MIBC correlated low TCR diversity and high neoantigen load with improved survival suggesting that tumor antigen specific immune responses are a key part of anti-tumor immunity (107). The gene discussed is CD4; the disease is neoplasm.